EVALUATION OF ANGIOGENESIS IN EWING SARCOMA

Florin Filip, Roxana Filip, Laurian Lucian Francu

Abstract


The most human tumours do not produce angiogenesis in the early stages. They can develop for months or years without vascular
support, and then perhaps due to the accumulation of mutations, the tumour cells change their phenotype towards
angiogenesis. It is thought that this switching would be explained by an increased production of angiogenic factors, and by the
loss of angiogenesis inhibitors. All these considerations have directed our research into the qualitative and quantitative
assessment of angiogenesis in the Ewing tumour in children. We have studied 42 anatomo-pathologically confirmed bone
tumours in children between 3-18 years. We used imunohystochemical marker antigen associated with factor VIII (von
Willebrand). Microvascular density was quantified in the area with the most active angiogenesis, using the Weibel parallel grid
from the PRODIT 5.2. program. In Ewing sarcoma angiogenesis is very intense, the microvascular density reaching the highest
values compared to other types of bone tumours. It is similar to grade 4 osteosarcoma and could be interpreted in the same way:
poor prognosis through the high risk of metastasis.


Keywords


angiogenesis, Ewing sarcoma, factor VIII, quantitative methods.

Full Text:

PDF

References


McCarthy EF, Frassica FJ. Primary bone tumors. In: Pathology of Bone and Joint Disorders. Philadelphia, WB Saunders, 1998, 258-61.

Pawar VR, More S, Patil PP. Cytological diagnosis of Ewing sarcoma clavicle. Indian Med Gaz 2011; CLXV:495-7.

Bordia S, Meena S, Meena BK, Rajak V. Fine-needle aspiration cytology of ewing′s sarcoma of thoracic spine with extension into the intradural space. Case Rep Oncol Med 2014; 2014:351-86.

Asotra S, Sharma S. Cytodiagnosis of Ewing's sarcoma and its confirmation by histopathology and immunohisto-chemistry.Clin Cancer Investig J, 2015; 4(3):396-8.

Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic witch during tumorigenesis. Cell, 1996, 86(3):353-64.

Barinaga M. Designing therapies that target tumor blood vessels. Science, 1997, 275, 482.

Barinaga M. New type of blood vessel found in tumors. Science, 1999; 285(5433):1475-8.

Claesson-Welsh L. Blood vessels as targets in tumor therapy. Ups J Med Sci. 2012; 117(2): 178–86.

Hsu SM, Raine L, Fanger H.Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.J Histochem Cytochem. 1981;29(4):577-80.

BussolatiG,Gugliotta P.Immunohistochemistry of actin in normal and neoplastic tissues. In Advances in Immunohistochemistry. DeLellis RA, Masson, New York, 1981, 225-8.

Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G.Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. WeiJ Natl Cancer Inst. 1992; 84(24):1875-87.

Frîncu DL, Frâncu LL, Filip F, Călin D. Apreciereaneovascularizaţieiînosteosarcoameleoaselor lungi.Rev. Med Chir, Iaşi, 2003, 107(3, suppl 1):159-63.

Zhou Z, Reddy K, Guan H, Kleinerman ES. VEGF, but not VEGF, stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo.Mol Cancer Res, 2007, 5(11): 1125-32.

DuBois SG, Marina N, Glade-Bender J. Angiogenesis and Vascular Targeting in Ewing Sarcoma: A Review of Preclinical and Clinical Data.Cancer. 2010; 116(3): 749–57.

Stewart KS, Kleinerman ES. Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents. Sarcoma, 2011, 2011:165837, 1-7.


Refbacks

  • There are currently no refbacks.